
Acurx will use the MRSA PolC structure to announce a next-wave inhibitor optimization milestone with Leiden researchers.
Antibiotic R&D is constrained by scientific risk and slow iteration cycles; structural biology that clarifies target binding can materially accelerate medicinal chemistry and partnering. MRSA remains a high-profile superbug, making the work both medically and politically salient.
AI reasoning
Antibiotic R&D is constrained by scientific risk and slow iteration cycles; structural biology that clarifies target binding can materially accelerate medicinal chemistry and partnering. MRSA remains a high-profile superbug, making the work both medically and politically salient.
Curated summary
Acurx Pharmaceuticals announced a scientific partnership with Leiden University Medical Center in the Netherlands to seek the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor. The company said the work is intended to speed development of new antibiotics and builds on a November 2025 Health-Holland grant and earlier research published in Nature Communications. Acurx framed the goal as developing systemically active drugs against Gram-positive pathogens that resist current antibiotics.
Supporting evidence
YouTube·WebsEdgeMedicineBroadly Focussed Translational Genetics Research - Leiden University Medical Center, The Netherlands
832 engagements2h ago
YouTube·Leids Universitair Medisch CentrumHypoVax
117 engagements2h ago
YouTube·Leids Universitair Medisch CentrumLUMC Planetaire gezondheid en duurzaamheid in het onderwijs ENG
111 engagements2h ago
YouTube·Civil CouncilFloor van der Does, - Leiden University Medical Center
90 engagements2h ago
YouTube·New to The Street TVAcurx Pharma Partners With Leiden University to Advance Next-Generation Antibiotics
66 engagements2h ago
YouTube·NewsOutAcurx Pharma Advances Antibiotic Program Toward Phase 3 C. diff Trials | NewsOut
2h ago
YouTube·NewsOutAcurx Pharma Reports Positive FDA Meeting for Ibuzatrelvir Phase 3 Program
2h ago
YouTube·WebsEdgeMedicineCenter for Endocrine Tumors Leiden – Leiden University Medical Center
2h ago
Source news
Acurx and Leiden University Medical Center team up to map MRSA PolC structure for next-generation antibiotics
The partnership targets the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor.















